Triple-acting Lytic Enzyme Treatment of Drug-Resistant and Intracellular Staphylococcus aureus

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Becker, Stephen C ^a   Roach, Dwayne R ^a,l   Chauhan, Vinita S ^b   Shen, Yang ^c,d,j   Foster Frey, Juli ^a   Powell, Anne M ^a   Bauchan, Gary ^a   Lease, Richard A ^a,i   Mohammadi, Homan ^a   Harty, William J ^a   Simmons, Chad ^a   Schmelcher, Mathias ^a,j   Camp, Mary ^a   Dong, Shengli ^f,k   Baker, John R ^f   Sheen, Tamsin R ^g   Doran, Kelly S ^g   Pritchard, David G ^f   Almeida, Raul A ^h   Nelson, Daniel C ^c,d   Marriott, Ian ^b   Lee, Jean C ^e   Donovan, David M ^a   more..

^a AGRICULTURAL RESEARCH SERVICE   (United States)

^b UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^c UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g SAN DIEGO STATE UNIVERSITY   (United States)

^h UNIVERSITY OF TENNESSEE   (United States)

ⁱ The Ohio State University   (United States)

^j ETH ZURICH   (Switzerland)

^k LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l INSTITUT PASTEUR   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; HYBRID PROTEIN; N ACETYLMURAMOYLALANINE AMIDASE;

ANIMAL; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; GENETICS; HETEROZYGOTE; HUMAN; MASTITIS; METABOLISM; MOUSE; OSTEOMYELITIS; PREVENTION AND CONTROL; RAT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; CARRIER STATE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HUMANS; MASTITIS; MICE; N-ACETYLMURAMOYL-L-ALANINE AMIDASE; OSTEOMYELITIS; RATS; RECOMBINANT FUSION PROTEINS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 84964800034     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep25063     Document Type: Article

References (57)

1. F. D. Lowy Staphylococcus aureus infections. N. Engl. J. Med. 339(8), 520 (1998).
2. P. C. Appelbaum Microbiology of antibiotic resistance in Staphylococcus aureus, Clin. Infect. Dis. 45 Suppl 3:S165-70, S165-S170 (2007).
3. E. Klein, D. L. Smith & R. Laxminarayan Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 13(12), 1840 (2007).
4. E. Y. Klein et al. The changing epidemiology of methicillin-resistant Staphylococcus aureus in the United States: a national observational study. Am. J. Epidemiol. 177(7), 666 (2013).
5. I. Plouin-Gaudon et al. Intracellular residency is frequently associated with recurrent Staphylococcus aureus rhinosinusitis. Rhinology. 44(4), 249 (2006).
6. A. Hebert et al. Demonstration of intracellular Staphylococcus aureus in bovine mastitis alveolar cells and macrophages isolated from naturally infected cow milk. FEMS Microbiol. Lett. 193(1), 57 (2000).
7. V. Peton & Loir, Y. Le Staphylococcus aureus in veterinary medicine. Infect. Genet. Evol. 21, 602 (2014).
8. S. S. Reilly et al. In vivo internalization of Staphylococcus aureus by embryonic chick osteoblasts. Bone. 26(1), 63 (2000).
9. J. K. Ellington et al. Intracellular Staphylococcus aureus and antibiotic resistance: implications for treatment of staphylococcal osteomyelitis. J Orthop. Res. 24(1), 87 (2006).
10. H. C. Yun, J. G. Branstetter & C. K. Murray Osteomyelitis in military personnel wounded in Iraq and Afghanistan. J. Trauma. 64 (2 Suppl), S163-S168 (2008).
11. S. M. Lehar et al. Novel antibody-Antibiotic conjugate eliminates intracellular S. aureus. Nature 527(7578), 323 (2015).
12. D. M Donovan et al. Peptidoglycan hydrolase enzyme fusions for treating multi-drug resistant pathogens. Biotech International 21(2), 6 (2009).
13. S. C. Becker, J. Foster-Frey & D. M. Donovan The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA. FEMS Microbiol Lett. 287(2), 185 (2008).
14. K. H. Schleifer & O. Kandler Peptidoglycan types of bacterial cell walls and their taxonomic implications, Bacteriol. Rev. 36(4), 407 (1972).
15. M. Schmelcher et al. Rapid multiplex detection and differentiation of Listeria cells by use of fluorescent phage endolysin cell wall binding domains. Appl. Environ. Microbiol. 76(17), 5745 (2010).
16. D. C. Nelson et al. Endolysins as antimicrobials. Adv. Virus Res. 83, 299 (2012).
17. M. Schmelcher, D. M. Donovan & M. J. Loessner Bacteriophage endolysins as novel antimicrobials. Future. Microbiol. 7(10), 1147 (2012).
18. Y. Shen et al. Phage-Based Enzybiotics, in Bacteriophages in Health and Disease, (eds. by Abedon S. et al.) 217-239 (CABI Press, Wallingford, 2012).
19. S. C. Becker et al. Differentially conserved staphylococcal SH3b-5 cell wall binding domains confer increased staphylolytic and streptolytic activity to a streptococcal prophage endolysin domain. Gene. 443(1-2), 32 (2009).
20. J. Mao et al. Chimeric Ply187 endolysin kills Staphylococcus aureus more effectively than the parental enzyme. FEMS Microbiol. Lett. 342(1), 30 (2013).
21. M. Schmelcher et al. Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands. Appl. Environ. Microbiol. 78(7), 2297 (2012).
22. J. Borysowski & A. Gorski, Fusion to cell-penetrating peptides will enable lytic enzymes to kill intracellular bacteria, Med. Hypotheses 74(1), 164 (2010).
23. H. P. Browder et al. Lysostaphin enzymatic mode of action. Biochem Biophys Res Commun 19(383), 389 (1965).
24. S. O'Flaherty et al. The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus. J. Bacteriol. 187(20), 7161 (2005).
25. S. C. Becker et al. LysK CHAP endopeptidase domain is required for lysis of live staphylococcal cells. FEMS Microbiol. Lett. 294(1), 52 (2009).
26. S. Walsh et al. Extended nasal residence time of lysostaphin and an anti-staphylococcal monoclonal antibody by delivery in semisolid or polymeric carriers. Pharm. Res. 21(10), 1770 (2004).
27. G. P. Dietz Cell-penetrating peptide technology to deliver chaperones and associated factors in diseases and basic research. Curr. Pharm. Biotechnol. 11(2), 167 (2010).
28. P. A. Pattee Distribution of Tn551 insertion sites responsible for auxotrophy on the Staphylococcus aureus chromosome. J. Bacteriol. 145(1), 479 (1981).
29. S. W. Perry, L. G. Epstein & H. A. Gelbard In situ trypan blue staining of monolayer cell cultures for permanent fixation and mounting. BioTechniques 22(6), 1020 (1997).
30. I. Marriott et al. Osteoblasts produce monocyte chemoattractant protein-1 in a murine model of Staphylococcus aureus osteomyelitis and infected human bone tissue. Bone. 37(4), 504 (2005).
31. V. A. Fischetti Bacteriophage lytic enzymes: novel anti-infectives. Trends Microbiol. 13(10), 491 (2005).
32. D. Nelson, L. Loomis & V. A. Fischetti Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc. Natl. Acad. Sci. USA 98(7), 4107 (2001).
33. P. Sass & G. Bierbaum Lytic Activity of Recombinant Bacteriophage {phi}11 and {phi}12 Endolysins on Whole Cells and Biofilms of Staphylococcus aureus. Appl. Environ. Microbiol. 73(1), 347 (2007).
34. A. Daniel et al. Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 54(4), 1603 (2010).
35. M. Pastagia et al. A Novel Chimeric Lysin Shows Superiority to Mupirocin for Skin Decolonization of Methicillin-Resistant and-Sensitive Staphylococcus aureus Strains. Antimicrob. Agents Chemother. 55(2), 738 (2011).
36. M. M. Gaspar et al. Developments on drug delivery systems for the treatment of mycobacterial infections. Curr. Top. Med. Chem. 8(7), 579 (2008).
37. M. A. Biel Photodynamic therapy of bacterial and fungal biofilm infections. Methods Mol. Biol. 635, 175-94, doi: 10.1007/978-1-60761-697-9-13. 175 (2010).
38. A. Gorski et al. Phage as a modulator of immune responses: practical implications for phage therapy. Adv. Virus Res. 83, 41 (2012), doi: 10.1016/B978-0-12-394438-2.00002-5.
39. M. J. Daley & E. R. Oldham Lysostaphin: immunogenicity of locally administered recombinant protein used in mastitis therapy. Vet. Immunol. Immunopathol. 31(3-4), 301 (1992).
40. J. M. Loeffler & V. A. Fischetti Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillinsensitive and-resistant Streptococcus pneumoniae strains. Antimicrob. Agents. Chemother. 47(1), 375 (2003).
41. J. Borysowski, B. Weber-Dabrowska & A. Gorski Bacteriophage endolysins as a novel class of antibacterial agents. Exp Biol Med (Maywood). 231(4), 366 (2006).
42. M. Schmelcher et al. Evolutionarily distinct bacteriophage endolysins featuring conserved peptidoglycan cleavage sites protect mice from MRSA infection. J Antimicrob Chemother. 70(5), 1453 (2015).
43. J. M. Loeffler, D. Nelson & V. A. Fischetti Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294(5549), 2170 (2001).
44. M. Gross et al. Key role of teichoic acid net charge in Staphylococcus aureus colonization of artificial surfaces. Infect. Immun. 69(5), 3423 (2001).
45. R. A. Almeida et al. Staphylococcus aureus invasion of bovine mammary epithelial cells. J Dairy Sci 79(6), 1021 (1996).
46. A. C. Schaffer et al. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect. Immun. 74(4), 2145 (2006).
47. D. E. Kerr et al. Lysostaphin expression in mammary glands confers protection against staphylococcal infection in transgenic mice. Nat. Biotechnol. 19(1), 66 (2001).
48. D. Derossi et al. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J. Biol. Chem. 271(30), 18188 (1996).
49. T. B. Wyman et al. Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers, Biochemistry. 36(10), 3008 (1997).
50. S. El-Andaloussi et al. A novel cell-penetrating peptide, M918, for efficient delivery of proteins and peptide nucleic acids. Mol. Ther. 15(10), 1820 (2007).
51. A. Scheller et al. Structural requirements for cellular uptake of alpha-helical amphipathic peptides. J. Pept. Sci. 5(4), 185 (1999).
52. Z. Mi et al. Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo. Mol. Ther. 2(4), 339 (2000).
53. A. Elmquist et al. VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions. Exp. Cell Res. 269(2), 237 (2001).
54. P. A. Wender et al. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. USA 97(24), 13003 (2000).
55. E. Vives, P. Brodin & B. Lebleu A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272(25), 16010 (1997).
56. M. Pooga et al. Cell penetration by transportan. FASEB J. 12(1), 67 (1998).
57. U. Soomets et al. Deletion analogues of transportan. Biochim. Biophys. Acta. 1467(1), 165 (2000).